This site is intended for health professionals only

Published on 23 August 2010

Share this story:
Twitter
LinkedIn

Panel supports Cymbalta expansion

teaser

A popular antidepressant treatment has been narrowly approved for use in chronic pain sufferers in the US.

Eli Lilly’s Cymbalta drug received the backing of a US Food and Drug Administration (FDA) panel which voted 8-6 in favour of expanding its indication for its treatment of chronic pain conditions.

It is currently used to treat depression, diabetic nerve pain and fibromyalgia and is Eli Lilly’s second biggest selling drug behind its flagship anti-psychotic drug Zyprexa.

Despite the panel’s approval, drug regulators are not required to follow the recommendation and could still bring to a halt any ambitions to market the drug as a treatment for chronic pain.

There is still confusion over how the drug actually works and which conditions it effectively treats after the FDA found conflicting results for its effectiveness in different pain disorders across a variety of patient groups.

Even so, Indianapolis-based Eli Lilly is still pushing for formal approval for Cymbalta, which is classed alongside Effexor and Pristig as a serotonin-norepinephrine reuptake inhibitor.

Cymbalta’s maker believes decreases chronic pain symptoms by manipulating serotonin levels.

Copyright Press Association 2010

Eli Lilly

US Food and Drug Administration



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn